AbbVie (ABBV) 10-Q 2 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Oct. 25, 2021
Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-35565
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	0001551152
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,767,880,465
NEW YORK STOCK EXCHANGE, INC. | Common stock
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
NEW YORK STOCK EXCHANGE, INC. | Sec 1.500 Senior Notes Due 2023
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.500% Senior Notes due 2023
Trading Symbol	ABBV23B
NEW YORK STOCK EXCHANGE, INC. | Sec 1.375 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.375% Senior Notes due 2024
Trading Symbol	ABBV24
NEW YORK STOCK EXCHANGE, INC. | Sec 1.250 Senior Notes Due 2024
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2024
Trading Symbol	ABBV24B
NEW YORK STOCK EXCHANGE, INC. | Sec 0.750 Senior Notes Due 2027
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
NEW YORK STOCK EXCHANGE, INC. | Sec 2.125 Senior Notes due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
NEW YORK STOCK EXCHANGE, INC. | Sec 2.625 Senior Notes Due 2028
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.625% Senior Notes due 2028
Trading Symbol	ABBV28B
NEW YORK STOCK EXCHANGE, INC. | Sec 2.125 Senior Notes Due 2029
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	2.125% Senior Notes due 2029
Trading Symbol	ABBV29
NEW YORK STOCK EXCHANGE, INC. | Sec 1.250 Senior Notes due 2031
Entity Information
Security Exchange Name	NYSE
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
CHICAGO STOCK EXCHANGE, INC | Common stock
Entity Information
Security Exchange Name	CHX
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net revenues	$ 14,342	$ 12,902	$ 41,311	$ 31,946
Cost of products sold	4,390	5,050	13,126	10,703
Selling, general and administrative	3,083	2,846	9,089	8,068
Research and development	1,673	1,706	5,257	4,667
Acquired in-process research and development	390	45	557	898
Other operating expense, net	500	0	432	0
Total operating costs and expenses	10,036	9,647	28,461	24,336
Operating earnings	4,306	3,255	12,850	7,610
Interest expense, net	585	620	1,813	1,662
Net foreign exchange loss	12	20	35	54
Other expense, net	21	115	2,284	989
Earnings before income tax expense	3,688	2,500	8,718	4,905
Income tax expense	508	187	1,214	321
Net earnings	3,180	2,313	7,504	4,584
Net earnings attributable to noncontrolling interest	1	5	6	4
Net earnings attributable to AbbVie Inc.	$ 3,179	$ 2,308	$ 7,498	$ 4,580
Per share data
Basic earnings per share (in dollars per share)	$ 1.78	$ 1.30	$ 4.21	$ 2.78
Diluted earnings per share (in dollars per share)	$ 1.78	$ 1.29	$ 4.19	$ 2.77
Weighted-average basic shares outstanding (in shares)	1,770	1,769	1,769	1,633
Weighted-average diluted shares outstanding (in shares)	1,777	1,774	1,776	1,637

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net earnings	$ 3,180	$ 2,313	$ 7,504	$ 4,584
Foreign currency translation adjustments, net of tax expense (benefit) of $(8) for the three months and $(32) for the nine months ended September 30, 2021 and $15 for the three months and $11 for the nine months ended September 30, 2020	(361)	512	(794)	726
Net investment hedging activities, net of tax expense (benefit) of $51 for the three months and $123 for the nine months ended September 30, 2021 and $(85) for the three months and $(125) for the nine months ended September 30, 2020	184	(314)	444	(455)
Pension and post-employment benefits, net of tax expense (benefit) of $17 for the three months and $50 for the nine months ended September 30, 2021 and $10 for the three months and $37 for nine months ended September 30, 2020	67	35	196	134
Cash flow hedging activities, net of tax expense (benefit) of $13 for the three months and $16 for the nine months ended September 30, 2021 and $(9) for the three months and $(13) for the nine months ended September 30, 2020	57	(57)	115	(68)
Other comprehensive income (loss)	(53)	176	(39)	337
Comprehensive income	3,127	2,489	7,465	4,921
Comprehensive income attributable to noncontrolling interest	1	5	6	4
Comprehensive income attributable to AbbVie Inc.	$ 3,126	$ 2,484	$ 7,459	$ 4,917

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ (8)	$ 15	$ (32)	$ 11
Net investment hedging activities, tax expense (benefit)	51	(85)	123	(125)
Pension and post-employment benefits, tax expense (benefit)	17	10	50	37
Cash flow hedging activities, tax expense (benefit)	$ 13	$ (9)	$ 16	$ (13)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and equivalents	$ 12,182	$ 8,449
Short-term investments	67	30
Accounts receivable, net	9,281	8,822
Inventories	3,094	3,310
Prepaid expenses and other	4,333	3,562
Total current assets	28,957	24,173
Investments	272	293
Property and equipment, net	5,130	5,248
Intangible assets, net	77,456	82,876
Goodwill	32,296	33,124
Other assets	4,747	4,851
Total assets	148,858	150,565
Current liabilities
Short-term borrowings	16	34
Current portion of long-term debt and finance lease obligations	6,656	8,468
Accounts payable and accrued liabilities	21,861	20,159
Total current liabilities	28,533	28,661
Long-term debt and finance lease obligations	74,049	77,554
Deferred income taxes	3,602	3,646
Other long-term liabilities	29,097	27,607
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,801,781,004 shares issued as of September 30, 2021 and 1,792,140,764 as of December 31, 2020	18	18
Common stock held in treasury, at cost, 33,974,112 shares as of September 30, 2021 and 27,007,945 as of December 31, 2020	(3,020)	(2,264)
Additional paid-in capital	18,108	17,384
Retained earnings	1,600	1,055
Accumulated other comprehensive loss	(3,156)	(3,117)
Total stockholders' equity	13,550	13,076
Noncontrolling interest	27	21
Total equity	13,577	13,097
Total liabilities and equity	$ 148,858	$ 150,565

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,801,781,004	1,792,140,764
Common stock held in treasury, at cost (in shares)	33,974,112	27,007,945

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury stock	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2019	$ (8,172)	$ 18	$ (24,504)	$ 15,193	$ 4,717	$ (3,596)	$ 0
Beginning balance (in shares) at Dec. 31, 2019		1,479
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	4,580	$ 0	0	0	4,580	0	0
Other comprehensive income (loss), net of tax	337	0	0	0	0	337	0
Dividends declared	(5,962)	0	0	0	(5,962)	0	0
Common shares and equity awards issued for acquisition of Allergan plc	24,409	$ 0	23,166	1,243	0	0	0
Common shares issued to Allergan plc stockholders (in shares)		286
Purchases of treasury stock	(682)	$ 0	(682)	0	0	0	0
Purchases of treasury stock (in shares)		(7)
Stock-based compensation plans and other	760	$ 0	48	712	0	0	0
Stock-based compensation plans and other (in shares)		7
Change in noncontrolling interest	19	$ 0	0	0	0	0	19
Ending balance at Sep. 30, 2020	15,289	$ 18	(1,972)	17,148	3,335	(3,259)	19
Ending balance (in shares) at Sep. 30, 2020		1,765
Beginning balance at Jun. 30, 2020	14,732	$ 18	(1,958)	16,953	3,130	(3,435)	24
Beginning balance (in shares) at Jun. 30, 2020		1,764
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	2,308	$ 0	0	0	2,308	0	0
Other comprehensive income (loss), net of tax	176	0	0	0	0	176	0
Dividends declared	(2,103)	0	0	0	(2,103)	0	0
Purchases of treasury stock	(20)	$ 0	(20)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	201	$ 0	6	195	0	0	0
Stock-based compensation plans and other (in shares)		1
Change in noncontrolling interest	(5)	$ 0	0	0	0	0	(5)
Ending balance at Sep. 30, 2020	15,289	$ 18	(1,972)	17,148	3,335	(3,259)	19
Ending balance (in shares) at Sep. 30, 2020		1,765
Beginning balance at Dec. 31, 2020	13,097	$ 18	(2,264)	17,384	1,055	(3,117)	21
Beginning balance (in shares) at Dec. 31, 2020		1,765
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	7,498	$ 0	0	0	7,498	0	0
Other comprehensive income (loss), net of tax	(39)	0	0	0	0	(39)	0
Dividends declared	(6,953)	0	0	0	(6,953)	0	0
Purchases of treasury stock	(803)	$ 0	(803)	0	0	0	0
Purchases of treasury stock (in shares)		(7)
Stock-based compensation plans and other	771	$ 0	47	724	0	0	0
Stock-based compensation plans and other (in shares)		10
Change in noncontrolling interest	6	$ 0	0	0	0	0	6
Ending balance at Sep. 30, 2021	13,577	$ 18	(3,020)	18,108	1,600	(3,156)	27
Ending balance (in shares) at Sep. 30, 2021		1,768
Beginning balance at Jun. 30, 2021	12,594	$ 18	(3,022)	17,936	740	(3,103)	25
Beginning balance (in shares) at Jun. 30, 2021		1,767
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	3,179	$ 0	0	0	3,179	0	0
Other comprehensive income (loss), net of tax	(53)	0	0	0	0	(53)	0
Dividends declared	(2,319)	0	0	0	(2,319)	0	0
Purchases of treasury stock	(6)	$ 0	(6)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	180	$ 0	8	172	0	0	0
Stock-based compensation plans and other (in shares)		1
Change in noncontrolling interest	2	$ 0	0	0	0	0	2
Ending balance at Sep. 30, 2021	$ 13,577	$ 18	$ (3,020)	$ 18,108	$ 1,600	$ (3,156)	$ 27
Ending balance (in shares) at Sep. 30, 2021		1,768

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Statement of Cash Flows [Abstract]
Net earnings	$ 7,504	$ 4,584
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	630	439
Amortization of intangible assets	5,912	3,967
Deferred income taxes	(153)	(498)
Change in fair value of contingent consideration liabilities	2,447	1,078
Stock-based compensation	563	617
Upfront costs and milestones related to collaborations	1,219	1,028
Gain on divestitures	(68)	0
Other, net	(114)	491
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(572)	(574)
Inventories	(30)	(193)
Prepaid expenses and other assets	(462)	190
Accounts payable and other liabilities	1,454	1,903
Income tax assets and liabilities, net	(628)	(298)
Cash flows from operating activities	17,702	12,734
Cash flows from investing activities
Acquisition of businesses, net of cash acquired	0	(38,138)
Other acquisitions and investments	(837)	(1,072)
Acquisitions of property and equipment	(600)	(519)
Purchases of investment securities	(73)	(47)
Sales and maturities of investment securities	88	1,464
Other, net	223	1,382
Cash flows from investing activities	(1,199)	(36,930)
Cash flows from financing activities
Proceeds from issuance of long-term debt	1,000	3,000
Repayments of long-term debt and finance lease obligations	(5,662)	(4,414)
Debt issuance costs	0	(20)
Dividends paid	(6,947)	(5,615)
Purchases of treasury stock	(803)	(682)
Proceeds from the exercise of stock options	169	109
Payments of contingent consideration liabilities	(480)	(212)
Other, net	22	28
Cash flows from financing activities	(12,701)	(7,806)
Effect of exchange rate changes on cash and equivalents	(69)	(32)
Net change in cash and equivalents	3,733	(32,034)
Cash and equivalents, beginning of period	8,449	39,924
Cash and equivalents, end of period	12,182	7,890
Issuance of common shares associated with acquisitions of businesses	$ 0	$ 23,979

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2020. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2019-12 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) . The standard includes simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. AbbVie adopted the standard in the first quarter of 2021. The adoption did not have a material impact on its consolidated financial statements.

Supplemental Financial Informat

Supplemental Financial Information	9 Months Ended
	Sep. 30, 2021
Supplemental Financial Information
Supplemental Financial Information	Supplemental Financial Information Interest Expense, Net Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Interest expense $ 596 $ 630 $ 1,843 $ 1,825 Interest income (11) (10) (30) (163) Interest expense, net $ 585 $ 620 $ 1,813 $ 1,662 Inventories (in millions) September 30, 2021 December 31, 2020 Finished goods $ 877 $ 1,318 Work-in-process 1,328 1,201 Raw materials 889 791 Inventories $ 3,094 $ 3,310 Property and Equipment, Net (in millions) September 30, 2021 December 31, 2020 Property and equipment, gross $ 10,803 $ 10,859 Accumulated depreciation (5,673) (5,611) Property and equipment, net $ 5,130 $ 5,248 Depreciation expense was $223 million for the three months and $630 million for the nine months ended September 30, 2021 and $175 million for the three months and $439 million for the nine months ended September 30, 2020.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method: Three months ended Nine months ended (in millions, except per share data) 2021 2020 2021 2020 Basic EPS Net earnings attributable to AbbVie Inc. $ 3,179 $ 2,308 $ 7,498 $ 4,580 Earnings allocated to participating securities 21 17 53 44 Earnings available to common shareholders $ 3,158 $ 2,291 $ 7,445 $ 4,536 Weighted-average basic shares outstanding 1,770 1,769 1,769 1,633 Basic earnings per share attributable to AbbVie Inc. $ 1.78 $ 1.30 $ 4.21 $ 2.78 Diluted EPS Net earnings attributable to AbbVie Inc. $ 3,179 $ 2,308 $ 7,498 $ 4,580 Earnings allocated to participating securities 21 17 53 44 Earnings available to common shareholders $ 3,158 $ 2,291 $ 7,445 $ 4,536 Weighted-average shares of common stock outstanding 1,770 1,769 1,769 1,633 Effect of dilutive securities 7 5 7 4 Weighted-average diluted shares outstanding 1,777 1,774 1,776 1,637 Diluted earnings per share attributable to AbbVie Inc. $ 1.78 $ 1.29 $ 4.19 $ 2.77 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions, and Ot

Licensing, Acquisitions, and Other Arrangements	9 Months Ended
	Sep. 30, 2021
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Acquisition of Allergan The acquisition of Allergan was accounted for as a business combination using the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of assets acquired and liabilities assumed was finalized during the three months ended June 30, 2021. Measurement period adjustments to the preliminary purchase price allocation during the six months ended June 30, 2021 included: (i) an increase to intangible assets of $710 million; (ii) an increase to deferred income tax liabilities of $148 million; (iii) other individually insignificant adjustments for a net increase to identifiable net assets of $2 million; and (iv) a corresponding decrease to goodwill of $564 million. The measurement period adjustments primarily resulted from the completion of the valuation of certain license agreement intangible assets based on facts and circumstances that existed as of the acquisition date and did not result from intervening events subsequent to such date. These adjustments did not have a significant impact on AbbVie's results of operations for the nine months ended September 30, 2021 and would not have had a significant impact on prior period results if these adjustments had been made as of the acquisition date. Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments totaled $837 million for the nine months ended September 30, 2021 and $1.1 billion for the nine months ended September 30, 2020. AbbVie recorded acquired in-process research and development (IPR&D) charges of $390 million for the three months and $557 million for the nine months ended September 30, 2021 and recorded acquired IPR&D charges of $45 million for the three months and $898 million for the nine months ended September 30, 2020. Soliton, Inc. In May 2021, AbbVie announced that it entered into a definitive agreement with Soliton, Inc. (Soliton) to acquire Soliton and RESONIC, its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. Under the terms of the transaction agreement, AbbVie will pay $22.60 per share in cash for each outstanding share of Soliton for an enterprise value of approximately $550 million. Closing of the transaction is subject to regulatory approval. Calico Life Sciences LLC In July 2021, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. This is the second collaboration extension and builds on the partnership established in 2014 and extended in 2018. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million and the term is extended for an additional three years. AbbVie’s contribution is payable in two equal installments beginning in 2023. Calico will be responsible for research and early development until 2025 and will advance collaboration projects into Phase 2a through 2030. Following completion of the Phase 2a studies, AbbVie will have the option to exclusively license the collaboration compounds. Upon exercise, AbbVie would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During the three months ended September 30, 2021, AbbVie recorded $500 million as other operating expense in the condensed consolidated statement of earnings related to its commitments under the agreement. TeneoOne and TNB-383B In September 2021, AbbVie acquired TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM). In February 2019, AbbVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie exercised its exclusive right to acquire TeneoOne and TNB-383B based on an interim analysis of an ongoing Phase 1 study and accounted for the transaction as an asset acquisition. Under the terms of the agreement, AbbVie made an exercise payment of $400 million which was recorded to IPR&D in the condensed consolidated statement of earnings for the three months ended September 30, 2021. The agreement also included additional payments of up to $250 million upon the achievement of certain development, regulatory and commercial milestones. REGENXBIO Inc. In September 2021, AbbVie and REGENXBIO Inc. (REGENXBIO) entered into a partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO and AbbVie will share equally in pre-tax profits from net revenues of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net revenues outside the U.S. Upon closing, AbbVie will make an upfront payment of $370 million which will be recorded to IPR&D in the consolidated statement of earnings. Closing of the transaction is subject to regulatory approval. The agreement also included additional payments of up to $1.4 billion upon the achievement of certain development, regulatory and commercial milestones. Genmab A/S In June 2020, AbbVie and Genmab A/S (Genmab) entered into a collaboration agreement to jointly develop and commercialize three of Genmab's early-stage investigational bispecific antibody therapeutics and entered into a discovery research collaboration for future differentiated antibody therapeutics for the treatment of cancer. Under the terms of the agreement, Genmab granted to AbbVie an exclusive license to its epcoritamab (DuoBody-CD3xCD20), DuoHexaBody-CD37 and DuoBody-CD3x5T4 programs. For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab will record net revenues in the U.S. and Japan, and the parties will share equally in pre-tax profits from these sales. Genmab will receive tiered royalties on remaining global sales. For the discovery research partnership, Genmab will conduct Phase 1 studies for these programs and AbbVie retains the right to opt-in to program development. AbbVie made an upfront payment of $750 million, which was recorded to IPR&D in the condensed consolidated statement of earnings for the three months ended June 30, 2020. The agreement also included additional payments of up to $3.2 billion upon the achievement of certain development, regulatory and commercial milestones for all programs.

Collaborations

Collaborations	9 Months Ended
	Sep. 30, 2021
Collaborative Arrangements [Abstract]
Collaborations	Collaborations The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting the periods ended September 30, 2021 and 2020. Collaboration with Janssen Biotech, Inc. In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton’s tyrosine kinase (BTK) and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States. The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs. In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 United States - Janssen's share of profits (included in cost of products sold) $ 518 $ 524 $ 1,497 $ 1,467 International - AbbVie's share of profits (included in net revenues) 265 251 816 750 Global - AbbVie's share of other costs (included in respective line items) 76 74 220 211 AbbVie’s receivable from Janssen, included in accounts receivable, net, was $298 million at September 30, 2021 and $283 million at December 31, 2020. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $471 million at September 30, 2021 and $562 million at December 31, 2020. Collaboration with Genentech, Inc. AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie’s net revenues. Genentech’s share of United States profits is included in AbbVie’s cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of selling, general and administrative (SG&A) expenses and global development costs as part of research and development (R&D) expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold. The following table shows the profit and cost sharing relationship between Genentech and AbbVie: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Genentech's share of profits, including royalties (included in cost of products sold) $ 187 $ 139 $ 514 $ 390 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 10 9 29 34 AbbVie's share of development costs (included in R&D) 34 27 110 88

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible AssetsGoodwill The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2020 $ 33,124 Measurement period adjustments (a) (564) Foreign currency translation adjustments and other (264) Balance as of September 30, 2021 $ 32,296 (a) Measurement period adjustments relate to the acquisition of Allergan (see Note 4). The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of September 30, 2021, there were no accumulated goodwill impairment losses. Intangible Assets, Net The following table summarizes intangible assets: September 30, 2021 December 31, 2020 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 87,880 $ (16,859) $ 71,021 $ 87,707 $ (11,620) $ 76,087 License agreements 8,486 (3,501) 4,985 7,828 (2,916) 4,912 Total definite-lived intangible assets 96,366 (20,360) 76,006 95,535 (14,536) 80,999 Indefinite-lived research and development 1,450 — 1,450 1,877 — 1,877 Total intangible assets, net $ 97,816 $ (20,360) $ 77,456 $ 97,412 $ (14,536) $ 82,876 Definite-Lived Intangible Assets The increase in the gross carrying amount of definite-lived intangible assets during the nine months ended September 30, 2021 was primarily due to the measurement period adjustments from the completion of the valuation of certain license agreements acquired in the Allergan acquisition. See Note 4 for additional information regarding these adjustments. Amortization expense was $1.9 billion for the three months and $5.9 billion for the nine months ended September 30, 2021 and $2.1 billion for the three months and $4.0 billion for the nine months ended September 30, 2020. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. Indefinite-Lived Intangible Assets Indefinite-lived intangible assets represents IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist.

Integration and Restructuring P

Integration and Restructuring Plans	9 Months Ended
	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Integration and Restructuring Plans	Integration and Restructuring PlansAllergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization. To achieve these integration objectives, AbbVie expects to incur total cumulative charges of approximately $2 billion through 2022. These costs will consist of severance and employee benefit costs (cash severance, non-cash severance including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses. The following table summarizes the charges associated with the Allergan acquisition integration plan: Severance and employee benefits Other integration Three months ended Nine months ended Three months ended Nine months ended (in millions) 2021 2020 2021 2020 2021 2020 2021 2020 Cost of products sold $ 2 $ 10 $ 8 $ 43 $ 44 $ 12 $ 84 $ 13 Research and development — 40 — 172 18 91 87 135 Selling, general and administrative 18 29 47 347 88 57 213 155 Total charges $ 20 $ 79 $ 55 $ 562 $ 150 $ 160 $ 384 $ 303 The following table summarizes the cash activity in the recorded liability associated with the integration plan for the nine months ended September 30, 2021: (in millions) Severance and employee benefits Other integration Accrued balance as of December 31, 2020 $ 367 $ 20 Charges 51 326 Payments and other adjustments (192) (341) Accrued balance as of September 30, 2021 $ 226 $ 5 Other Restructuring AbbVie recorded restructuring charges of $13 million for the three months and $56 million for the nine months ended September 30, 2021 and $11 million for the three months and $42 million for the nine months ended September 30, 2020. The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2021: (in millions) Accrued balance as of December 31, 2020 $ 90 Restructuring charges 52 Payments and other adjustments (89) Accrued balance as of September 30, 2021 $ 53

Financial Instruments and Fair

Financial Instruments and Fair Value Measures	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measures	Financial Instruments and Fair Value MeasuresRisk Management Policy See Note 11 to the company’s Annual Report on Form 10-K for the year ended December 31, 2020 for a summary of AbbVie’s risk management policy and use of derivative instruments. Financial Instruments Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $1.5 billion at September 30, 2021 and December 31, 2020, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of September 30, 2021 are reclassified from accumulated other comprehensive income (loss) (AOCI) and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement. In the third quarter of 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in November 2019 and the resulting net gain was recognized in other comprehensive income (loss). This gain is reclassified to interest expense, net over the term of the related debt. The company is party to interest rate swap contracts designated as cash flow hedges with notional amounts totaling $1.5 billion at September 30, 2021 and $2.3 billion at December 31, 2020. The effect of the hedge contracts is to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses are included in AOCI and are reclassified to interest expense, net over the lives of the floating-rate debt. The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the condensed consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $8.1 billion at September 30, 2021 and $8.6 billion at December 31, 2020. The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had foreign currency forward exchange contracts with notional amounts totaling €4.3 billion at September 30, 2021 and €971 million at December 31, 2020. The company also had an aggregate principal amount of senior Euro notes designated as net investment hedges of €5.9 billion at September 30, 2021 and €6.6 billion at December 31, 2020. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument. The company is party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $3.8 billion at September 30, 2021 and $4.8 billion December 31, 2020. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges. The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption September 30, 2021 December 31, 2020 Balance sheet caption September 30, 2021 December 31, 2020 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 47 $ 2 Accounts payable and accrued liabilities $ — $ 82 Designated as cash flow hedges Other assets — — Other long-term liabilities — 6 Designated as net investment hedges Prepaid expenses and other 71 — Accounts payable and accrued liabilities — 11 Not designated as hedges Prepaid expenses and other 22 49 Accounts payable and accrued liabilities 33 33 Interest rate swap contracts Designated as cash flow hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 1 14 Designated as cash flow hedges Other assets — — Other long-term liabilities 12 20 Designated as fair value hedges Prepaid expenses and other — 7 Accounts payable and accrued liabilities — — Designated as fair value hedges Other assets 68 131 Other long-term liabilities 3 — Total derivatives $ 208 $ 189 $ 49 $ 166 While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets. The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges $ 43 $ (52) $ 67 $ (5) Designated as net investment hedges 101 (56) 186 (32) Interest rate swap contracts designated as cash flow hedges (1) (1) — (53) Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $11 million into cost of products sold for foreign currency cash flow hedges, pre-tax losses of $12 million into interest expense, net for interest rate swap cash flow hedges and pre-tax gains of $24 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months. Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $141 million for the three months and pre-tax gains of $397 million for the nine months ended September 30, 2021 and pre-tax losses of $340 million for the three months and pre-tax losses of $532 million for the nine months ended September 30, 2020. The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Nine months ended (in millions) Statement of earnings caption 2021 2020 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ (28) $ 15 $ (62) $ 15 Designated as net investment hedges Interest expense, net 7 3 16 16 Not designated as hedges Net foreign exchange loss (25) 31 (53) 36 Treasury rate lock agreements designated as cash flow hedges Interest expense, net 6 6 18 18 Interest rate swap contracts Designated as cash flow hedges Interest expense, net (6) (8) (20) (10) Designated as fair value hedges Interest expense, net (5) 1 (73) 398 Debt designated as hedged item in fair value hedges Interest expense, net 5 (1) 73 (398) Fair Value Measures The fair value hierarchy consists of the following three levels: • Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2021: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 12,182 $ 4,026 $ 8,156 $ — Money market funds and time deposits 10 — 10 — Debt securities 64 — 64 — Equity securities 133 117 16 — Interest rate swap contracts 68 — 68 — Foreign currency contracts 140 — 140 — Total assets $ 12,597 $ 4,143 $ 8,454 $ — Liabilities Interest rate swap contracts $ 16 $ — $ 16 $ — Foreign currency contracts 33 — 33 — Contingent consideration 14,919 — — 14,919 Total liabilities $ 14,968 $ — $ 49 $ 14,919 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2020: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 8,449 $ 2,758 $ 5,691 $ — Money market funds and time deposits 12 — 12 — Debt securities 50 — 50 — Equity securities 159 149 10 — Interest rate swap contracts 138 — 138 — Foreign currency contracts 51 — 51 — Total assets $ 8,859 $ 2,907 $ 5,952 $ — Liabilities Interest rate swap contracts $ 34 $ — $ 34 $ — Foreign currency contracts 132 — 132 — Contingent consideration 12,997 — — 12,997 Total liabilities $ 13,163 $ — $ 166 $ 12,997 Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. The fair value of the company's contingent consideration liabilities as of September 30, 2021 was calculated using the following significant unobservable inputs: Range Weighted average (a) Discount rate 0.1% - 2.6% 1.5 % Probability of payment for unachieved milestones 56% - 92% 87 % Probability of payment for royalties by indication (b) 56% - 100% 95 % Projected year of payments 2021 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at September 30, 2021. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs: Nine months ended (in millions) 2021 2020 Beginning balance $ 12,997 $ 7,340 Additions (a) — 121 Change in fair value recognized in net earnings 2,447 1,078 Payments (525) (212) Ending balance $ 14,919 $ 8,327 (a) Represents contingent consideration liabilities assumed in the Allergan acquisition. The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2021 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Short-term borrowings $ 16 $ 16 $ — $ 16 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 6,656 6,672 6,410 262 — Long-term debt and finance lease obligations, excluding fair value hedges 73,880 81,537 80,228 1,309 — Total liabilities $ 80,552 $ 88,225 $ 86,638 $ 1,587 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2020 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Short-term borrowings $ 34 $ 34 $ — $ 34 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 8,461 8,542 8,249 293 — Long-term debt and finance lease obligations, excluding fair value hedges 77,283 87,761 86,137 1,624 — Total liabilities $ 85,778 $ 96,337 $ 94,386 $ 1,951 $ — AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $132 million as of September 30, 2021 and $102 million as of December 31, 2020. No significant cumulative upward or downward adjustments have been recorded for these investments as of September 30, 2021. Concentrations of Risk Of total net accounts receivable, three U.S. wholesalers accounted for 75% as of September 30, 2021 and 72% as of December 31, 2020, and substantially all of AbbVie’s net revenues in the United States were to these three wholesalers. Humira (adalimumab) is AbbVie’s single largest product and accounted for approximately 37% of AbbVie’s total net revenues for the nine months ended September 30, 2021 and 46% for the nine months ended September 30, 2020. Debt and Credit Facilities In April 2021, the company repaid $1.8 billion aggregate principal amount of 2.3% senior notes that were scheduled to mature in May 2021. In May 2021, the company repaid €750 million aggregate principal amount of 0.5% senior euro notes that were scheduled to mature in June 2021. These repayments were made by exercising, under the terms of the notes, 30-day early redemptions at 100% of the principal amounts. The company also repaid $750 million aggregate principal amount of floating rate senior notes at maturity in May 2021. In September 2021, the company refinanced its $1.0 billion floating rate three-year term loan. As part of the refinancing, the company repaid the existing $1.0 billion term loan due May 2023 and borrowed $1.0 billion under a new term loan at a lower floating rate. All other significant terms of the loan, including the maturity date, remained unchanged after the refinancing. In September 2021, the company repaid $1.2 billion aggregate principal amount of 5.0% senior notes that were scheduled to mature in December 2021. This repayment was made by exercising, under the terms of the notes, 90-day early redemption at 100% of the principal amount. In connection with the acquisition of Allergan, in May 2020, the company borrowed $3.0 billion under a $6.0 billion term loan credit agreement, consisting of a $1.0 billion floating rate three-year term loan tranche and a $2.0 billion floating rate five-year term loan tranche. Subsequent to these borrowings, AbbVie terminated the unused commitments of the lenders under the term loan. In May 2020, AbbVie completed its previously announced offers to exchange any and all outstanding notes of certain series issued by Allergan for new notes to be issued by AbbVie and cash. Following the settlement of the exchange offers, AbbVie issued $14.0 billion and €3.1 billion of new notes in exchange for the Allergan notes tendered in the exchange offers. The aggregate principal amount of Allergan notes that remained outstanding following the settlement of the exchange offers was approximately $1.5 billion and €635 million. The exchange transaction was accounted for as a modification of the assumed debt instruments. In September 2020, the company repaid $650 million aggregate principal amount of 3.375% Allergan exchange notes at maturity. In May 2020, the company also repaid $3.8 billion aggregate principal amount of 2.5% senior notes at maturity. Short-Term Borrowings There were no commercial paper borrowings outstanding as of September 30, 2021 and December 31, 2020. There were no commercial paper borrowings issued during the nine months ended September 30, 2021. The weighted-average interest rate on commercial paper borrowings was 1.8% for the nine months ended September 30, 2020.

Post-Employment Benefits

Post-Employment Benefits	9 Months Ended
	Sep. 30, 2021
Postemployment Benefits [Abstract]
Post-Employment Benefits	Post-Employment Benefits The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Nine months ended Three months ended Nine months ended (in millions) 2021 2020 2021 2020 2021 2020 2021 2020 Service cost $ 110 $ 93 $ 331 $ 277 $ 12 $ 10 $ 36 $ 31 Interest cost 59 68 177 196 5 8 14 25 Expected return on plan assets (166) (148) (498) (426) — — — — Amortization of prior service cost (credit) 1 1 2 2 (10) (1) (29) (3) Amortization of actuarial loss 72 56 217 169 8 8 24 20 Net periodic benefit cost $ 76 $ 70 $ 229 $ 218 $ 15 $ 25 $ 45 $ 73

Equity

Equity	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Equity	EquityStock-Based Compensation In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program, including an increase in the number of shares available for issuance of 44 million shares and an extension of the program to May 2031. Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Cost of products sold $ 9 $ 11 $ 39 $ 37 Research and development 47 54 181 200 Selling, general and administrative 79 97 343 380 Pre-tax compensation expense 135 162 563 617 Tax benefit 27 32 101 109 After-tax compensation expense $ 108 $ 130 $ 462 $ 508 Stock Options During the nine months ended September 30, 2021, primarily in connection with the company's annual grant, AbbVie granted 1.1 million stock options with a weighted-average grant-date fair value of $16.28. As of September 30, 2021, $12 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years. RSUs and Performance Shares During the nine months ended September 30, 2021, primarily in connection with the company's annual grant, AbbVie granted 7.4 million RSUs and performance shares with a weighted-average grant-date fair value of $105.39. As of September 30, 2021, $712 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years. Cash Dividends The following table summarizes quarterly cash dividends declared during 2021 and 2020: 2021 2020 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/29/21 02/15/22 $ 1.41 10/30/20 02/16/21 $ 1.30 09/10/21 11/15/21 $ 1.30 09/11/20 11/16/20 $ 1.18 06/17/21 08/16/21 $ 1.30 06/17/20 08/14/20 $ 1.18 02/18/21 05/14/21 $ 1.30 02/20/20 05/15/20 $ 1.18 Stock Repurchase Program The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes. AbbVie repurchased 5 million shares for $550 million during the nine months ended September 30, 2021 and 6 million shares for $500 million during the nine months ended September 30, 2020. AbbVie's remaining stock repurchase authorization was approximately $2.6 billion as of September 30, 2021. Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2021: (in millions) Foreign currency Net investment hedging activities Pension and post-employment Cash flow hedging Total Balance as of December 31, 2020 $ 583 $ (790) $ (3,067) $ 157 $ (3,117) Other comprehensive income (loss) before reclassifications (794) 457 27 60 (250) Net losses (gains) reclassified from accumulated other comprehensive loss — (13) 169 55 211 Net current-period other comprehensive income (loss) (794) 444 196 115 (39) Balance as of September 30, 2021 $ (211) $ (346) $ (2,871) $ 272 $ (3,156) Other comprehensive loss for the nine months ended September 30, 2021 included foreign currency translation adjustments totaling a loss of $794 million and the offsetting impact of net investment hedging activities totaling a gain of $444 million, which were principally due to the impact of the weakening of the Euro on the translation of the company’s Euro-denominated assets. The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2020: (in millions) Foreign currency Net investment hedging activities Pension Cash flow hedging Total Balance as of December 31, 2019 $ (928) $ 9 $ (2,965) $ 288 $ (3,596) Other comprehensive income (loss) before reclassifications 726 (443) (14) (49) 220 Net losses (gains) reclassified from accumulated other comprehensive loss — (12) 148 (19) 117 Net current-period other comprehensive income (loss) 726 (455) 134 (68) 337 Balance as of September 30, 2020 $ (202) $ (446) $ (2,831) $ 220 $ (3,259) Other comprehensive income for the nine months ended September 30, 2020 included foreign currency translation adjustments totaling a gain of $726 million and the offsetting impact of net investment hedging activities totaling a loss of $455 million, which were principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets. The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended Nine months ended (in millions) (brackets denote gains) 2021 2020 2021 2020 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (7) $ (3) $ (16) $ (16) Tax expense 1 1 3 4 Total reclassifications, net of tax $ (6) $ (2) $ (13) $ (12) Pension and post-employment benefits Amortization of actuarial losses and other (b) $ 71 $ 63 $ 214 $ 188 Tax benefit (15) (13) (45) (40) Total reclassifications, net of tax $ 56 $ 50 $ 169 $ 148 Cash flow hedging activities Losses (gains) on foreign currency forward exchange contracts (c) $ 28 $ (15) $ 62 $ (15) Gains on treasury rate lock agreements (a) (6) (6) (18) (18) Losses on interest rate swap contracts (a) 6 8 20 10 Tax expense (benefit) (4) 3 (9) 4 Total reclassifications, net of tax $ 24 $ (10) $ 55 $ (19) (a) Amounts are included in interest expense, net (see Note 8). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9). (c) Amounts are included in cost of products sold (see Note 8).

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe effective tax rate was 14% for the three and nine months ended September 30, 2021 compared to 7% for the three and nine months ended September 30, 2020. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and collaborations. The increase in the effective tax rate for the three and nine months ended September 30, 2021 over the prior year was primarily due to the jurisdictional mix of earnings resulting from collaboration activities and accretion on contingent consideration in 2021.Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next 12 months by up to $258 million.

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. The most significant matters are described below. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott Laboratories (Abbott) and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Antitrust Litigation Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payors. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation , MDL No. 2460. In August 2019, the court certified a class of direct purchasers of Niaspan. In June 2020 and August 2021, the court denied the end-payors' motions to certify a class. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In September 2014, the Federal Trade Commission (FTC) filed a lawsuit, FTC v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2011 patent litigation with two generic companies regarding AndroGel was sham litigation and the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC’s settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of $448 million, plus prejudgment interest. The court denied the FTC’s request for injunctive relief. In September 2020, the United States Court of Appeals for the Third Circuit reversed the district court’s finding of sham litigation with respect to one generic company and affirmed with respect to the other but held the FTC lacked authority to obtain a disgorgement remedy and vacated the district court’s award. The Third Circuit also affirmed the district court’s denial of the FTC’s injunction request and reinstated the FTC’s settlement-related claim for further proceedings in the district court. In July 2021, the FTC voluntarily dismissed the remaining claims in its lawsuit with prejudice. In August 2019, direct purchasers of AndroGel filed a lawsuit, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al., against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that 2006 patent litigation settlements and related agreements by Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) with three generic companies violated federal antitrust law, and also making allegations similar to those in FTC v. AbbVie Inc. (above). In May 2020, Perrigo Company and related entities filed a lawsuit against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, making sham litigation allegations similar to those in FTC v. AbbVie Inc. (above). In October 2020, the Perrigo lawsuit was transferred to the United States District Court for New Jersey. In September 2021, the New Jersey court granted AbbVie’s motion for judgment on the pleadings in the Perrigo lawsuit, dismissing it with prejudice. Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect Humira purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s Humira patent portfolio violated state and federal antitrust laws. The court consolidated these lawsuits as In re: Humira (Adalimumab) Antitrust Litigation . In June 2020, the court dismissed the consolidated litigation with prejudice. The plaintiffs have appealed the dismissal. Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2009 and 2010 patent litigation settlements involving Namenda entered into between Forest and generic companies and other conduct by Forest involving Namenda, violated state antitrust, unfair and deceptive trade practices, and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys’ fees. The lawsuits, purported class actions filed by indirect purchasers of Namenda, are consolidated as In re: Namenda Indirect Purchaser Antitrust Litigation in the United States District Court for the Southern District of New York. Lawsuits are pending against Allergan Inc. generally alleging that Allergan’s petitioning to the U.S. Patent Office and Food and Drug Administration and other conduct by Allergan involving Restasis violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief and attorneys’ fees. The lawsuits, certified as a class action filed on behalf of indirect purchasers of Restasis, are consolidated for pre-trial purposes in the United States District Court for the Eastern District of New York under the MDL Rules as In re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation, MDL No. 2819. In May 2021, the parties reached an agreement to settle this matter that is subject to court approval. Lawsuits are pending against Forest Laboratories, LLC and others generally alleging that 2012 and 2013 patent litigation settlements involving Bystolic with six generic manufacturers violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages, injunctive relief, and attorneys’ fees. The lawsuits, purported class actions filed on behalf of direct and indirect purchasers of Bystolic, are consolidated as In re: Bystolic Antitrust Litigation in the United States District Court for the Southern District of New York. Government Proceedings Lawsuits are pending against Allergan and other defendants generally alleging that they improperly marketed and/or distributed prescription opioid products. Approximately 3,200 matters are pending against Allergan. The federal court cases are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 300 of the claims are pending in various state courts. The plaintiffs in these cases, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals, and personal injury claimants, generally seek compensatory and punitive damages. In July 2019, the New Mexico Attorney General filed a lawsuit, State of New Mexico ex rel. Balderas v. AbbVie Inc., et al. , in New Mexico District Court for Santa Fe County against AbbVie and other companies alleging their marketing of AndroGel violated New Mexico’s Unfair Practices Act. In October 2020, the state added a claim under the New Mexico False Advertising Act. Shareholder and Securities Litigation In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2019 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. The court granted motions dismissing the claims of three investment-fund plaintiffs, which they appealed. In March 2021, in the first of those appeals, the dismissal was affirmed. One of these plaintiffs refiled its lawsuit in New York state court in June 2020 while the appeal of its dismissal in Illinois is pending. In November 2020, the New York Supreme Court for the County of New York dismissed that lawsuit, which is being appealed. In September 2021, the Illinois court granted AbbVie’s motion for summary judgment against all remaining plaintiffs on all the remaining claims, dismissing them with prejudice. The plaintiffs have appealed the dismissals. In October 2018, a federal securities purported class action lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2017 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs’ motion to certify a class. Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan's textured breast implants. The lawsuits, which were filed by Allergan shareholders, have been consolidated in the United States District Court for the Southern District of New York as In re: Allergan plc Securities Litigation. The plaintiffs generally seek compensatory damages and attorneys’ fees. In September 2019, the court partially granted Allergan's motion to dismiss. In September 2020, the court denied plaintiffs’ class certification motion because it found the lead plaintiff to be an inadequate representative of the proposed class but allowed another putative class member to propose itself as a new lead plaintiff. In December 2020, the court appointed a new lead plaintiff. In September 2021, the court granted plaintiffs’ motion to certify a class. Lawsuits are pending against Allergan and certain of its current and former officers alleging they made misrepresentations and omissions regarding Allergan’s former Actavis generics unit and its alleged anticompetitive conduct with other generic drug companies. The lawsuits were filed by Allergan shareholders and consist of three purported class actions and one individual action seeking monetary damages and attorney’s fees that have been consolidated in the U.S. District Court for the District of New Jersey as In re: Allergan Generic Drug Pricing Securities Litigation . In July 2021, the parties reached an agreement to settle the class action lawsuits, which is pending court approval. Product Liability and General Litigation In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al. , was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator seeks damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. Intellectual Property Litigation AbbVie Inc. and AbbVie Biotechnology Ltd are seeking to enforce their patent rights relating to adalimumab (a drug AbbVie sells under the trademark Humira). In April 2021 and May 2021, cases were filed in the United States District Court for the Northern District of Illinois against Alvotech hf. AbbVie alleges defendant’s proposed biosimilar adalimumab product infringes certain AbbVie patents and seeks declaratory and injunctive relief. In August 2021, the court denied Defendant’s motion to dismiss on jurisdictional grounds in the first case; a motion in the second case remains pending. The court has set a trial on a subset of patents for August 2022. The court order provides that Alvotech will stay off the market until that decision. Litigation on the remaining patents is stayed. In May 2021, Alvotech hf. and its U.S. subsidiary Alvotech USA, Inc. filed a declaratory judgment action in the United States Eastern District of Virginia seeking a declaration that the same patents at issue in AbbVie’s April 2021 Illinois case are invalid or not infringed. AbbVie has filed a motion to dismiss or transfer that case to the Northern District of Illinois. Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark Imbruvica). Cases were filed in the United States District Court for the District of Delaware in March 2019 against Alvogen Pine Brook LLC and Natco Pharma Ltd. In August 2021, the court issued a decision holding all asserted patents infringed and valid. The judgment precludes Defendants from obtaining regulatory approval and launching until the last patent expires in 2036. On August 30, 2021, Defendants appealed. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of Imbruvica, is the co-plaintiff in these suits.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	Segment InformationAbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. The following table details AbbVie’s worldwide net revenues: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Immunology Humira United States $ 4,613 $ 4,189 $ 12,777 $ 11,819 International 812 951 2,583 2,861 Total $ 5,425 $ 5,140 $ 15,360 $ 14,680 Skyrizi United States $ 679 $ 379 $ 1,725 $ 934 International 117 56 319 131 Total $ 796 $ 435 $ 2,044 $ 1,065 Rinvoq United States $ 348 $ 191 $ 889 $ 409 International 105 24 245 41 Total $ 453 $ 215 $ 1,134 $ 450 Hematologic Oncology Imbruvica United States $ 1,109 $ 1,119 $ 3,207 $ 3,140 Collaboration revenues 265 251 816 750 Total $ 1,374 $ 1,370 $ 4,023 $ 3,890 Venclexta United States $ 237 $ 204 $ 685 $ 596 International 255 148 647 376 Total $ 492 $ 352 $ 1,332 $ 972 Aesthetics Botox Cosmetic (a) United States $ 356 $ 237 $ 1,027 $ 384 International 189 156 579 235 Total $ 545 $ 393 $ 1,606 $ 619 Juvederm Collection (a) United States $ 159 $ 115 $ 478 $ 171 International 195 159 625 216 Total $ 354 $ 274 $ 1,103 $ 387 Other Aesthetics (a) United States $ 305 $ 265 $ 968 $ 392 International 47 35 149 50 Total $ 352 $ 300 $ 1,117 $ 442 Neuroscience Botox Therapeutic (a) United States $ 534 $ 429 $ 1,451 $ 683 International 111 94 329 137 Total $ 645 $ 523 $ 1,780 $ 820 Vraylar (a) United States $ 461 $ 358 $ 1,239 $ 550 Duodopa United States $ 23 $ 25 $ 73 $ 75 International 104 98 310 290 Total $ 127 $ 123 $ 383 $ 365 Ubrelvy (a) United States $ 162 $ 38 $ 369 $ 60 Other Neuroscience (a) United States $ 166 $ 203 $ 489 $ 306 International 5 4 13 6 Total $ 171 $ 207 $ 502 $ 312 Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Eye Care Lumigan/Ganfort (a) United States $ 63 $ 62 $ 201 $ 97 International 75 87 229 128 Total $ 138 $ 149 $ 430 $ 225 Alphagan/Combigan (a) United States $ 89 $ 84 $ 271 $ 131 International 39 39 117 61 Total $ 128 $ 123 $ 388 $ 192 Restasis (a) United States $ 305 $ 284 $ 884 $ 422 International 14 15 42 21 Total $ 319 $ 299 $ 926 $ 443 Other Eye Care (a) United States $ 128 $ 119 $ 375 $ 173 International 158 150 488 224 Total $ 286 $ 269 $ 863 $ 397 Women's Health Lo Loestrin (a) United States $ 105 $ 129 $ 300 $ 207 International 2 5 9 7 Total $ 107 $ 134 $ 309 $ 214 Orilissa/Oriahnn United States $ 37 $ 24 $ 102 $ 84 International 1 1 4 3 Total $ 38 $ 25 $ 106 $ 87 Other Women's Health (a) United States $ 57 $ 74 $ 153 $ 108 International — 6 5 8 Total $ 57 $ 80 $ 158 $ 116 Other Key Products Mavyret United States $ 183 $ 185 $ 557 $ 565 International 243 229 726 784 Total $ 426 $ 414 $ 1,283 $ 1,349 Creon United States $ 310 $ 282 $ 864 $ 810 Lupron United States $ 134 $ 99 $ 456 $ 461 International 46 34 135 110 Total $ 180 $ 133 $ 591 $ 571 Linzess/Constella (a) United States $ 253 $ 240 $ 728 $ 370 International 8 8 23 11 Total $ 261 $ 248 $ 751 $ 381 Synthroid United States $ 188 $ 189 $ 571 $ 577 All other (a) $ 547 $ 829 $ 2,079 $ 1,972 Total net revenues $ 14,342 $ 12,902 $ 41,311 $ 31,946 (a) Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2019-12 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) . The standard includes simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. AbbVie adopted the standard in the first quarter of 2021. The adoption did not have a material impact on its consolidated financial statements.

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	9 Months Ended
	Sep. 30, 2021
Supplemental Financial Information
Schedule of interest expense, net	Interest Expense, Net Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Interest expense $ 596 $ 630 $ 1,843 $ 1,825 Interest income (11) (10) (30) (163) Interest expense, net $ 585 $ 620 $ 1,813 $ 1,662
Schedule of inventories	Inventories (in millions) September 30, 2021 December 31, 2020 Finished goods $ 877 $ 1,318 Work-in-process 1,328 1,201 Raw materials 889 791 Inventories $ 3,094 $ 3,310
Schedule of property and equipment, net	Property and Equipment, Net (in millions) September 30, 2021 December 31, 2020 Property and equipment, gross $ 10,803 $ 10,859 Accumulated depreciation (5,673) (5,611) Property and equipment, net $ 5,130 $ 5,248

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per share, impact of two-class method	The following table summarizes the impact of the two-class method: Three months ended Nine months ended (in millions, except per share data) 2021 2020 2021 2020 Basic EPS Net earnings attributable to AbbVie Inc. $ 3,179 $ 2,308 $ 7,498 $ 4,580 Earnings allocated to participating securities 21 17 53 44 Earnings available to common shareholders $ 3,158 $ 2,291 $ 7,445 $ 4,536 Weighted-average basic shares outstanding 1,770 1,769 1,769 1,633 Basic earnings per share attributable to AbbVie Inc. $ 1.78 $ 1.30 $ 4.21 $ 2.78 Diluted EPS Net earnings attributable to AbbVie Inc. $ 3,179 $ 2,308 $ 7,498 $ 4,580 Earnings allocated to participating securities 21 17 53 44 Earnings available to common shareholders $ 3,158 $ 2,291 $ 7,445 $ 4,536 Weighted-average shares of common stock outstanding 1,770 1,769 1,769 1,633 Effect of dilutive securities 7 5 7 4 Weighted-average diluted shares outstanding 1,777 1,774 1,776 1,637 Diluted earnings per share attributable to AbbVie Inc. $ 1.78 $ 1.29 $ 4.19 $ 2.77

Collaborations (Tables)

Collaborations (Tables)	9 Months Ended
	Sep. 30, 2021
Janssen Biotech Inc.
Collaborative and license agreements
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 United States - Janssen's share of profits (included in cost of products sold) $ 518 $ 524 $ 1,497 $ 1,467 International - AbbVie's share of profits (included in net revenues) 265 251 816 750 Global - AbbVie's share of other costs (included in respective line items) 76 74 220 211
Genentech, Inc.
Collaborative and license agreements
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Genentech and AbbVie: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Genentech's share of profits, including royalties (included in cost of products sold) $ 187 $ 139 $ 514 $ 390 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 10 9 29 34 AbbVie's share of development costs (included in R&D) 34 27 110 88

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of changes in the carrying amount of goodwill	The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2020 $ 33,124 Measurement period adjustments (a) (564) Foreign currency translation adjustments and other (264) Balance as of September 30, 2021 $ 32,296 (a) Measurement period adjustments relate to the acquisition of Allergan (see Note 4).
Summary of definite-lived intangible assets	The following table summarizes intangible assets: September 30, 2021 December 31, 2020 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 87,880 $ (16,859) $ 71,021 $ 87,707 $ (11,620) $ 76,087 License agreements 8,486 (3,501) 4,985 7,828 (2,916) 4,912 Total definite-lived intangible assets 96,366 (20,360) 76,006 95,535 (14,536) 80,999 Indefinite-lived research and development 1,450 — 1,450 1,877 — 1,877 Total intangible assets, net $ 97,816 $ (20,360) $ 77,456 $ 97,412 $ (14,536) $ 82,876
Summary of indefinite-lived intangible assets	The following table summarizes intangible assets: September 30, 2021 December 31, 2020 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 87,880 $ (16,859) $ 71,021 $ 87,707 $ (11,620) $ 76,087 License agreements 8,486 (3,501) 4,985 7,828 (2,916) 4,912 Total definite-lived intangible assets 96,366 (20,360) 76,006 95,535 (14,536) 80,999 Indefinite-lived research and development 1,450 — 1,450 1,877 — 1,877 Total intangible assets, net $ 97,816 $ (20,360) $ 77,456 $ 97,412 $ (14,536) $ 82,876

Integration and Restructuring_2

Integration and Restructuring Plans (Tables)	9 Months Ended
	Sep. 30, 2021
Allergan integration plan
Restructuring charges
Summary of charges associated with integration plan	The following table summarizes the charges associated with the Allergan acquisition integration plan: Severance and employee benefits Other integration Three months ended Nine months ended Three months ended Nine months ended (in millions) 2021 2020 2021 2020 2021 2020 2021 2020 Cost of products sold $ 2 $ 10 $ 8 $ 43 $ 44 $ 12 $ 84 $ 13 Research and development — 40 — 172 18 91 87 135 Selling, general and administrative 18 29 47 347 88 57 213 155 Total charges $ 20 $ 79 $ 55 $ 562 $ 150 $ 160 $ 384 $ 303
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the recorded liability associated with the integration plan for the nine months ended September 30, 2021: (in millions) Severance and employee benefits Other integration Accrued balance as of December 31, 2020 $ 367 $ 20 Charges 51 326 Payments and other adjustments (192) (341) Accrued balance as of September 30, 2021 $ 226 $ 5
Other restructuring
Restructuring charges
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the restructuring reserve for the nine months ended September 30, 2021: (in millions) Accrued balance as of December 31, 2020 $ 90 Restructuring charges 52 Payments and other adjustments (89) Accrued balance as of September 30, 2021 $ 53

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measures (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Summary of amounts and location of derivatives on the condensed consolidated balance sheets	The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption September 30, 2021 December 31, 2020 Balance sheet caption September 30, 2021 December 31, 2020 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 47 $ 2 Accounts payable and accrued liabilities $ — $ 82 Designated as cash flow hedges Other assets — — Other long-term liabilities — 6 Designated as net investment hedges Prepaid expenses and other 71 — Accounts payable and accrued liabilities — 11 Not designated as hedges Prepaid expenses and other 22 49 Accounts payable and accrued liabilities 33 33 Interest rate swap contracts Designated as cash flow hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 1 14 Designated as cash flow hedges Other assets — — Other long-term liabilities 12 20 Designated as fair value hedges Prepaid expenses and other — 7 Accounts payable and accrued liabilities — — Designated as fair value hedges Other assets 68 131 Other long-term liabilities 3 — Total derivatives $ 208 $ 189 $ 49 $ 166
Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges $ 43 $ (52) $ 67 $ (5) Designated as net investment hedges 101 (56) 186 (32) Interest rate swap contracts designated as cash flow hedges (1) (1) — (53)
Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges $ 43 $ (52) $ 67 $ (5) Designated as net investment hedges 101 (56) 186 (32) Interest rate swap contracts designated as cash flow hedges (1) (1) — (53)
Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings	The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 10 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Nine months ended (in millions) Statement of earnings caption 2021 2020 2021 2020 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ (28) $ 15 $ (62) $ 15 Designated as net investment hedges Interest expense, net 7 3 16 16 Not designated as hedges Net foreign exchange loss (25) 31 (53) 36 Treasury rate lock agreements designated as cash flow hedges Interest expense, net 6 6 18 18 Interest rate swap contracts Designated as cash flow hedges Interest expense, net (6) (8) (20) (10) Designated as fair value hedges Interest expense, net (5) 1 (73) 398 Debt designated as hedged item in fair value hedges Interest expense, net 5 (1) 73 (398)
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis	The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of September 30, 2021: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 12,182 $ 4,026 $ 8,156 $ — Money market funds and time deposits 10 — 10 — Debt securities 64 — 64 — Equity securities 133 117 16 — Interest rate swap contracts 68 — 68 — Foreign currency contracts 140 — 140 — Total assets $ 12,597 $ 4,143 $ 8,454 $ — Liabilities Interest rate swap contracts $ 16 $ — $ 16 $ — Foreign currency contracts 33 — 33 — Contingent consideration 14,919 — — 14,919 Total liabilities $ 14,968 $ — $ 49 $ 14,919 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2020: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 8,449 $ 2,758 $ 5,691 $ — Money market funds and time deposits 12 — 12 — Debt securities 50 — 50 — Equity securities 159 149 10 — Interest rate swap contracts 138 — 138 — Foreign currency contracts 51 — 51 — Total assets $ 8,859 $ 2,907 $ 5,952 $ — Liabilities Interest rate swap contracts $ 34 $ — $ 34 $ — Foreign currency contracts 132 — 132 — Contingent consideration 12,997 — — 12,997 Total liabilities $ 13,163 $ — $ 166 $ 12,997
Summary of significant level 3 unobservable inputs	The fair value of the company's contingent consideration liabilities as of September 30, 2021 was calculated using the following significant unobservable inputs: Range Weighted average (a) Discount rate 0.1% - 2.6% 1.5 % Probability of payment for unachieved milestones 56% - 92% 87 % Probability of payment for royalties by indication (b) 56% - 100% 95 % Projected year of payments 2021 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
Schedule of changes in fair value of Level 3 inputs	The following table presents the changes in fair value of total contingent consideration liabilities which are measured using Level 3 inputs: Nine months ended (in millions) 2021 2020 Beginning balance $ 12,997 $ 7,340 Additions (a) — 121 Change in fair value recognized in net earnings 2,447 1,078 Payments (525) (212) Ending balance $ 14,919 $ 8,327
Schedule of book values, approximate fair values and bases used to measure certain financial instruments	The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of September 30, 2021 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Short-term borrowings $ 16 $ 16 $ — $ 16 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 6,656 6,672 6,410 262 — Long-term debt and finance lease obligations, excluding fair value hedges 73,880 81,537 80,228 1,309 — Total liabilities $ 80,552 $ 88,225 $ 86,638 $ 1,587 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2020 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant other Significant unobservable inputs Liabilities Short-term borrowings $ 34 $ 34 $ — $ 34 $ — Current portion of long-term debt and finance lease obligations, excluding fair value hedges 8,461 8,542 8,249 293 — Long-term debt and finance lease obligations, excluding fair value hedges 77,283 87,761 86,137 1,624 — Total liabilities $ 85,778 $ 96,337 $ 94,386 $ 1,951 $ —

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	9 Months Ended
	Sep. 30, 2021
Postemployment Benefits [Abstract]
Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans	The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Nine months ended Three months ended Nine months ended (in millions) 2021 2020 2021 2020 2021 2020 2021 2020 Service cost $ 110 $ 93 $ 331 $ 277 $ 12 $ 10 $ 36 $ 31 Interest cost 59 68 177 196 5 8 14 25 Expected return on plan assets (166) (148) (498) (426) — — — — Amortization of prior service cost (credit) 1 1 2 2 (10) (1) (29) (3) Amortization of actuarial loss 72 56 217 169 8 8 24 20 Net periodic benefit cost $ 76 $ 70 $ 229 $ 218 $ 15 $ 25 $ 45 $ 73

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Summary of share-based compensation expense	Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the Amended Plan and is summarized as follows: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Cost of products sold $ 9 $ 11 $ 39 $ 37 Research and development 47 54 181 200 Selling, general and administrative 79 97 343 380 Pre-tax compensation expense 135 162 563 617 Tax benefit 27 32 101 109 After-tax compensation expense $ 108 $ 130 $ 462 $ 508
Summary of quarterly cash dividends	The following table summarizes quarterly cash dividends declared during 2021 and 2020: 2021 2020 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/29/21 02/15/22 $ 1.41 10/30/20 02/16/21 $ 1.30 09/10/21 11/15/21 $ 1.30 09/11/20 11/16/20 $ 1.18 06/17/21 08/16/21 $ 1.30 06/17/20 08/14/20 $ 1.18 02/18/21 05/14/21 $ 1.30 02/20/20 05/15/20 $ 1.18
Summary of changes in balances of each component of accumulated other comprehensive loss	The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2021: (in millions) Foreign currency Net investment hedging activities Pension and post-employment Cash flow hedging Total Balance as of December 31, 2020 $ 583 $ (790) $ (3,067) $ 157 $ (3,117) Other comprehensive income (loss) before reclassifications (794) 457 27 60 (250) Net losses (gains) reclassified from accumulated other comprehensive loss — (13) 169 55 211 Net current-period other comprehensive income (loss) (794) 444 196 115 (39) Balance as of September 30, 2021 $ (211) $ (346) $ (2,871) $ 272 $ (3,156) The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2020: (in millions) Foreign currency Net investment hedging activities Pension Cash flow hedging Total Balance as of December 31, 2019 $ (928) $ 9 $ (2,965) $ 288 $ (3,596) Other comprehensive income (loss) before reclassifications 726 (443) (14) (49) 220 Net losses (gains) reclassified from accumulated other comprehensive loss — (12) 148 (19) 117 Net current-period other comprehensive income (loss) 726 (455) 134 (68) 337 Balance as of September 30, 2020 $ (202) $ (446) $ (2,831) $ 220 $ (3,259)
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss	The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended Nine months ended (in millions) (brackets denote gains) 2021 2020 2021 2020 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (7) $ (3) $ (16) $ (16) Tax expense 1 1 3 4 Total reclassifications, net of tax $ (6) $ (2) $ (13) $ (12) Pension and post-employment benefits Amortization of actuarial losses and other (b) $ 71 $ 63 $ 214 $ 188 Tax benefit (15) (13) (45) (40) Total reclassifications, net of tax $ 56 $ 50 $ 169 $ 148 Cash flow hedging activities Losses (gains) on foreign currency forward exchange contracts (c) $ 28 $ (15) $ 62 $ (15) Gains on treasury rate lock agreements (a) (6) (6) (18) (18) Losses on interest rate swap contracts (a) 6 8 20 10 Tax expense (benefit) (4) 3 (9) 4 Total reclassifications, net of tax $ 24 $ (10) $ 55 $ (19) (a) Amounts are included in interest expense, net (see Note 8). (b) Amounts are included in the computation of net periodic benefit cost (see Note 9). (c) Amounts are included in cost of products sold (see Note 8).

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of worldwide net revenues	The following table details AbbVie’s worldwide net revenues: Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Immunology Humira United States $ 4,613 $ 4,189 $ 12,777 $ 11,819 International 812 951 2,583 2,861 Total $ 5,425 $ 5,140 $ 15,360 $ 14,680 Skyrizi United States $ 679 $ 379 $ 1,725 $ 934 International 117 56 319 131 Total $ 796 $ 435 $ 2,044 $ 1,065 Rinvoq United States $ 348 $ 191 $ 889 $ 409 International 105 24 245 41 Total $ 453 $ 215 $ 1,134 $ 450 Hematologic Oncology Imbruvica United States $ 1,109 $ 1,119 $ 3,207 $ 3,140 Collaboration revenues 265 251 816 750 Total $ 1,374 $ 1,370 $ 4,023 $ 3,890 Venclexta United States $ 237 $ 204 $ 685 $ 596 International 255 148 647 376 Total $ 492 $ 352 $ 1,332 $ 972 Aesthetics Botox Cosmetic (a) United States $ 356 $ 237 $ 1,027 $ 384 International 189 156 579 235 Total $ 545 $ 393 $ 1,606 $ 619 Juvederm Collection (a) United States $ 159 $ 115 $ 478 $ 171 International 195 159 625 216 Total $ 354 $ 274 $ 1,103 $ 387 Other Aesthetics (a) United States $ 305 $ 265 $ 968 $ 392 International 47 35 149 50 Total $ 352 $ 300 $ 1,117 $ 442 Neuroscience Botox Therapeutic (a) United States $ 534 $ 429 $ 1,451 $ 683 International 111 94 329 137 Total $ 645 $ 523 $ 1,780 $ 820 Vraylar (a) United States $ 461 $ 358 $ 1,239 $ 550 Duodopa United States $ 23 $ 25 $ 73 $ 75 International 104 98 310 290 Total $ 127 $ 123 $ 383 $ 365 Ubrelvy (a) United States $ 162 $ 38 $ 369 $ 60 Other Neuroscience (a) United States $ 166 $ 203 $ 489 $ 306 International 5 4 13 6 Total $ 171 $ 207 $ 502 $ 312 Three months ended Nine months ended (in millions) 2021 2020 2021 2020 Eye Care Lumigan/Ganfort (a) United States $ 63 $ 62 $ 201 $ 97 International 75 87 229 128 Total $ 138 $ 149 $ 430 $ 225 Alphagan/Combigan (a) United States $ 89 $ 84 $ 271 $ 131 International 39 39 117 61 Total $ 128 $ 123 $ 388 $ 192 Restasis (a) United States $ 305 $ 284 $ 884 $ 422 International 14 15 42 21 Total $ 319 $ 299 $ 926 $ 443 Other Eye Care (a) United States $ 128 $ 119 $ 375 $ 173 International 158 150 488 224 Total $ 286 $ 269 $ 863 $ 397 Women's Health Lo Loestrin (a) United States $ 105 $ 129 $ 300 $ 207 International 2 5 9 7 Total $ 107 $ 134 $ 309 $ 214 Orilissa/Oriahnn United States $ 37 $ 24 $ 102 $ 84 International 1 1 4 3 Total $ 38 $ 25 $ 106 $ 87 Other Women's Health (a) United States $ 57 $ 74 $ 153 $ 108 International — 6 5 8 Total $ 57 $ 80 $ 158 $ 116 Other Key Products Mavyret United States $ 183 $ 185 $ 557 $ 565 International 243 229 726 784 Total $ 426 $ 414 $ 1,283 $ 1,349 Creon United States $ 310 $ 282 $ 864 $ 810 Lupron United States $ 134 $ 99 $ 456 $ 461 International 46 34 135 110 Total $ 180 $ 133 $ 591 $ 571 Linzess/Constella (a) United States $ 253 $ 240 $ 728 $ 370 International 8 8 23 11 Total $ 261 $ 248 $ 751 $ 381 Synthroid United States $ 188 $ 189 $ 571 $ 577 All other (a) $ 547 $ 829 $ 2,079 $ 1,972 Total net revenues $ 14,342 $ 12,902 $ 41,311 $ 31,946 (a) Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.

Supplemental Financial Inform_3

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Interest Expense, Net
Interest expense	$ 596	$ 630	$ 1,843	$ 1,825
Interest income	(11)	(10)	(30)	(163)
Interest expense, net	585	620	1,813	1,662
Inventories
Finished goods	877		877		$ 1,318
Work-in-process	1,328		1,328		1,201
Raw materials	889		889		791
Inventories	3,094		3,094		3,310
Property and Equipment
Property and equipment, gross	10,803		10,803		10,859
Accumulated depreciation	(5,673)		(5,673)		(5,611)
Property and equipment, net	5,130		5,130		$ 5,248
Depreciation expense	$ 223	$ 175	$ 630	$ 439

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Basic EPS
Net earnings attributable to AbbVie Inc.	$ 3,179	$ 2,308	$ 7,498	$ 4,580
Earnings allocated to participating securities	21	17	53	44
Earnings available to common shareholders	$ 3,158	$ 2,291	$ 7,445	$ 4,536
Weighted-average basic shares outstanding (in shares)	1,770	1,769	1,769	1,633
Basic earnings per share (in dollars per share)	$ 1.78	$ 1.30	$ 4.21	$ 2.78
Diluted EPS
Net earnings attributable to AbbVie Inc.	$ 3,179	$ 2,308	$ 7,498	$ 4,580
Earnings allocated to participating securities	21	17	53	44
Earnings available to common shareholders	$ 3,158	$ 2,291	$ 7,445	$ 4,536
Weighted-average basic shares outstanding (in shares)	1,770	1,769	1,769	1,633
Effect of dilutive securities (in shares)	7	5	7	4
Weighted-average diluted shares outstanding (in shares)	1,777	1,774	1,776	1,637
Diluted earnings per share (in dollars per share)	$ 1.78	$ 1.29	$ 4.19	$ 2.77

Licensing, Acquisitions, and _2

Licensing, Acquisitions, and Other Arrangements - Acquisition of Allergan (Details) - USD ($) $ in Millions		6 Months Ended	9 Months Ended
		Jun. 30, 2021	Sep. 30, 2021
Business Acquisition
Goodwill, Purchase Accounting Adjustments	[1]		$ 564
Allergan plc
Business Acquisition
Intangible assets measurement period adjustments		$ 710
Deferred income tax liabilities measurement period adjustments		148
Other net measurement period adjustments		2
Goodwill, Purchase Accounting Adjustments		$ 564
[1]	(a) Measurement period adjustments relate to the acquisition of Allergan (see Note 4).

Licensing, Acquisitions, and _3

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ / shares in Units, $ in Millions	Nov. 02, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Collaborative and license agreements
Cash outflows related to other acquisitions and investments					$ (837)	$ (1,072)
Acquired in-process research and development		$ 390	$ 45		557	898
Additional contribution from Calico		500
Other operating expense, net		500	$ 0		432	$ 0
Forecast | Soliton, Inc.
Collaborative and license agreements
Cash per share received by Soliton shareholders (in dollars per share)	$ 22.60
Total consideration	$ 550
TeneoOne and TNB-383B | Collaborative arrangement | In-process research and development
Collaborative and license agreements
Acquired in-process research and development		400
TeneoOne and TNB-383B | Collaborative arrangement | Maximum
Collaborative and license agreements
Potential payments under agreement certain milestones		250			$ 250
Calico Life Sciences LLC | Collaborative arrangement
Collaborative and license agreements
Additional contribution from AbbVie		500
Other operating expense, net		$ 500
REGENXBIO Inc. | Collaborative arrangement | Forecast | In-process research and development
Collaborative and license agreements
Acquired in-process research and development	370
REGENXBIO Inc. | Collaborative arrangement | Maximum | Forecast
Collaborative and license agreements
Potential payments under agreement certain milestones	$ 1,400
Genmab A/S | Collaborative arrangement | In-process research and development
Collaborative and license agreements
Acquired in-process research and development				$ 750
Genmab A/S | Collaborative arrangement | Maximum
Collaborative and license agreements
Potential payments under agreement certain milestones				$ 3,200

Collaborations (Details)

Collaborations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Collaborative and license agreements
AbbVie's receivable from Janssen	$ 9,281		$ 9,281		$ 8,822
AbbVie's payable to Janssen	21,861		21,861		20,159
Janssen Biotech Inc. | Collaborative arrangement
Collaborative and license agreements
Milestone payments	200		$ 200
Share of collaboration development costs responsible by Janssen (as a percent)			60.00%
Share of collaboration development costs responsible by the entity (as a percent)			40.00%
Global - AbbVie's share of other costs (included in respective line items)	76	$ 74	$ 220	$ 211
AbbVie's receivable from Janssen	298		298		283
AbbVie's payable to Janssen	471		471		$ 562
Janssen Biotech Inc. | Collaborative arrangement | United States
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	518	524	1,497	1,467
Janssen Biotech Inc. | Collaborative arrangement | International
Collaborative and license agreements
International - AbbVie's share of profits (included in net revenues)	265	251	816	750
Genentech, Inc. | Collaborative arrangement
Collaborative and license agreements
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	187	139	514	390
AbbVie's share of development costs (included in R&D)	34	27	110	88
Genentech, Inc. | Collaborative arrangement | United States
Collaborative and license agreements
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	$ 10	$ 9	$ 29	$ 34

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 33,124,000,000
Goodwill measurement period adjustments	(564,000,000)	[1]
Foreign currency translation adjustments and other	(264,000,000)
Balance at the end of the period	32,296,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses	$ 0
[1]	(a) Measurement period adjustments relate to the acquisition of Allergan (see Note 4).

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets
Gross carrying amount	$ 96,366		$ 96,366		$ 95,535
Accumulated amortization	(20,360)		(20,360)		(14,536)
Net carrying amount	76,006		76,006		80,999
Indefinite-lived research and development	1,450		1,450		1,877
Total intangible assets gross carrying amount	97,816		97,816		97,412
Intangible assets, net	77,456		77,456		82,876
Amortization expense	1,900	$ 2,100	5,912	$ 3,967
Developed product rights
Finite-Lived Intangible Assets
Gross carrying amount	87,880		87,880		87,707
Accumulated amortization	(16,859)		(16,859)		(11,620)
Net carrying amount	71,021		71,021		76,087
License agreements
Finite-Lived Intangible Assets
Gross carrying amount	8,486		8,486		7,828
Accumulated amortization	(3,501)		(3,501)		(2,916)
Net carrying amount	$ 4,985		$ 4,985		$ 4,912

Integration and Restructuring_3

Integration and Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Allergan integration plan
Restructuring charges
Integration related costs	$ 2,000		$ 2,000
Allergan integration plan | Severance and employee benefits
Restructuring charges
Charges associated with integration or restructuring plans	20	$ 79	55	$ 562
Restructuring reserve rollforward
Accrued balance beginning of the period			367
Restructuring charges			51
Payments and other adjustments			(192)
Accrued balance end of the period	226		226
Allergan integration plan | Severance and employee benefits | Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	2	10	8	43
Allergan integration plan | Severance and employee benefits | Research and development
Restructuring charges
Charges associated with integration or restructuring plans	0	40	0	172
Allergan integration plan | Severance and employee benefits | Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	18	29	47	347
Allergan integration plan | Other integration
Restructuring charges
Charges associated with integration or restructuring plans	150	160	384	303
Restructuring reserve rollforward
Accrued balance beginning of the period			20
Restructuring charges			326
Payments and other adjustments			(341)
Accrued balance end of the period	5		5
Allergan integration plan | Other integration | Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans	44	12	84	13
Allergan integration plan | Other integration | Research and development
Restructuring charges
Charges associated with integration or restructuring plans	18	91	87	135
Allergan integration plan | Other integration | Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans	88	57	213	155
Other restructuring
Restructuring charges
Charges associated with integration or restructuring plans	13	$ 11	56	$ 42
Restructuring reserve rollforward
Accrued balance beginning of the period			90
Restructuring charges			52
Payments and other adjustments			(89)
Accrued balance end of the period	$ 53		$ 53

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measures - Financial Instruments (Details)	9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)
Derivative instruments, notional amount and fair value
Amount excluded from the assessment of effectiveness for cash flow hedges	$ 0	$ 0
Amount excluded from the assessment of effectiveness for fair value hedges	0	$ 0
Fair value - Derivatives in asset position	208,000,000			$ 189,000,000
Fair value - Derivatives in liability position	49,000,000			166,000,000
Designated as hedging instrument | Net investment hedges | Senior notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes | €			€ 5,900,000,000		€ 6,600,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	$ 1,500,000,000			1,500,000,000
Duration of forward exchange contracts	18 months
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold	6 months
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	$ 47,000,000			2,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			82,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0			0
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			6,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments | €			€ 4,300,000,000		€ 971,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	71,000,000			0
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			11,000,000
Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments						$ 10,000,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	1,500,000,000			2,300,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0			0
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	1,000,000			14,000,000
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0			0
Designated as hedging instrument | Interest rate swap contracts | Cash flow hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	12,000,000			20,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	3,800,000,000			4,800,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	0			7,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	0			0
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other assets
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	68,000,000			131,000,000
Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other long-term liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	3,000,000			0
Not designated as hedging instrument | Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	8,100,000,000			8,600,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other
Derivative instruments, notional amount and fair value
Fair value - Derivatives in asset position	22,000,000			49,000,000
Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Fair value - Derivatives in liability position	$ 33,000,000			$ 33,000,000

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Cost of products sold
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months	$ 11		$ 11
Interest expense, net
Gain (loss) on derivatives
Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months	(12)		(12)
Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months	24		24
Interest expense, net | Fair value hedges
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings	5	$ (1)	73	$ (398)
Designated as hedging instrument | Senior notes
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	141	(340)	397	(532)
Foreign currency forward exchange contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	43	(52)	67	(5)
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income	101	(56)	186	(32)
Foreign currency forward exchange contracts | Designated as hedging instrument | Cost of products sold | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	(28)	15	(62)	15
Foreign currency forward exchange contracts | Designated as hedging instrument | Interest expense, net | Net investment hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	7	3	16	16
Foreign currency forward exchange contracts | Not designated as hedges | Net foreign exchange loss
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	(25)	31	(53)	36
Treasury rate lock agreements | Designated as hedging instrument | Interest expense, net | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	6	6	18	18
Designated as fair value hedges | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	(1)	(1)	0	(53)
Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	(6)	(8)	(20)	(10)
Designated as fair value hedges | Designated as hedging instrument | Interest expense, net | Fair value hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidate statements of earnings	$ (5)	$ 1	$ (73)	$ 398

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Assets
Foreign currency contracts	$ 208	$ 189
Liabilities
Foreign currency contracts	49	166
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Total liabilities	86,638	94,386
Fair Value, Recurring
Assets
Cash and equivalents	12,182	8,449
Debt securities	64	50
Equity securities	133	159
Interest rate swap contracts	68	138
Total assets	12,597	8,859
Liabilities
Interest rate swap contracts	16	34
Contingent consideration	14,919	12,997
Total liabilities	14,968	13,163
Fair Value, Recurring | Foreign currency contracts
Assets
Foreign currency contracts	140	51
Liabilities
Foreign currency contracts	33	132
Fair Value, Recurring | Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	4,026	2,758
Debt securities	0	0
Equity securities	117	149
Interest rate swap contracts	0	0
Total assets	4,143	2,907
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Recurring | Quoted prices in active markets for identical assets (Level 1) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Fair Value, Recurring | Significant other observable inputs (Level 2)
Assets
Cash and equivalents	8,156	5,691
Debt securities	64	50
Equity securities	16	10
Interest rate swap contracts	68	138
Total assets	8,454	5,952
Liabilities
Interest rate swap contracts	16	34
Contingent consideration	0	0
Total liabilities	49	166
Fair Value, Recurring | Significant other observable inputs (Level 2) | Foreign currency contracts
Assets
Foreign currency contracts	140	51
Liabilities
Foreign currency contracts	33	132
Fair Value, Recurring | Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Debt securities	0	0
Equity securities	0	0
Interest rate swap contracts	0	0
Total assets	0	0
Liabilities
Interest rate swap contracts	0	0
Contingent consideration	14,919	12,997
Total liabilities	14,919	12,997
Fair Value, Recurring | Significant unobservable inputs (Level 3) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Money market funds and time deposits | Fair Value, Recurring
Assets
Money market funds and time deposits	10	12
Money market funds and time deposits | Fair Value, Recurring | Quoted prices in active markets for identical assets (Level 1)
Assets
Money market funds and time deposits	0	0
Money market funds and time deposits | Fair Value, Recurring | Significant other observable inputs (Level 2)
Assets
Money market funds and time deposits	10	12
Money market funds and time deposits | Fair Value, Recurring | Significant unobservable inputs (Level 3)
Assets
Money market funds and time deposits	$ 0	$ 0

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)	Sep. 30, 2021
Weighted average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.015	[1]
Weighted average | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.87	[1]
Weighted average | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.95	[1],[2]
Weighted average | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	2,027	[1]
Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.001
Minimum | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.56
Minimum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.56	[2]
Minimum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	2,021
Minimum | Probability of payment for royalties excluding early stage or approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.56	[2]
Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.026
Maximum | Probability of payment for unachieved milestones
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.92
Maximum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	1	[2]
Maximum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	2,034
Maximum | Probability of payment for royalties excluding early stage or approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	0.89	[2]
[1]	(a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.
[2]	(b) Excluding approved indications, the estimated probability of payment ranged from 56% to 89% at September 30, 2021.

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020
Transfers of assets or liabilities between the fair value measurement levels
Transfers of assets into Level 3 of the fair value hierarchy		$ 0
Transfers of assets out of Level 3 of the fair value hierarchy		0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]
Transfers of liabilities into Level 3 of the fair value hierarchy		0
Transfers of liabilities out of Level 3 of the fair value hierarchy		0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance		12,997,000,000	$ 7,340,000,000
Additions	[1]	0	121,000,000
Change in fair value recognized in net earnings		2,447,000,000	1,078,000,000
Payments		(525,000,000)	(212,000,000)
Ending balance		$ 14,919,000,000	$ 8,327,000,000
[1]	(a) Represents contingent consideration liabilities assumed in the Allergan acquisition.

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 132	$ 102
Quoted prices in active markets for identical assets (Level 1)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	6,410	8,249
Long-term debt and finance lease obligations, excluding fair value hedges	80,228	86,137
Total liabilities	86,638	94,386
Book value
Liabilities
Short-term borrowings	16	34
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	6,656	8,461
Long-term debt and finance lease obligations, excluding fair value hedges	73,880	77,283
Total liabilities	80,552	85,778
Approximate fair value
Liabilities
Short-term borrowings	16	34
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	6,672	8,542
Long-term debt and finance lease obligations, excluding fair value hedges	81,537	87,761
Total liabilities	88,225	96,337
Approximate fair value | Quoted prices in active markets for identical assets (Level 1)
Liabilities
Short-term borrowings	0	0
Approximate fair value | Significant other observable inputs (Level 2)
Liabilities
Short-term borrowings	16	34
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	262	293
Long-term debt and finance lease obligations, excluding fair value hedges	1,309	1,624
Total liabilities	1,587	1,951
Approximate fair value | Significant unobservable inputs (Level 3)
Liabilities
Short-term borrowings	0	0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	$ 0	$ 0

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accounts receivable, net
Concentration of Risk
Number of principal customers	3
Accounts receivable, net | Geographic risk | Principal US customers
Concentration of Risk
Concentrations risk (as a percent)	75.00%		72.00%
Total revenues | HUMIRA | Humira
Concentration of Risk
Concentrations risk (as a percent)	37.00%	46.00%

Financial Instruments and Fa_10

Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) € in Millions, $ in Millions	1 Months Ended				3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	May 31, 2021USD ($)	Sep. 30, 2020USD ($)	May 31, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2021EUR (€)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	May 31, 2020EUR (€)
Debt and Credit Facilities [Line Items]
Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security							$ 5,662	$ 4,414
2.30% senior notes due 2021 | Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt					$ 1,800
Stated interest rate (as a percent)					2.30%	2.30%
0.50% senior euro notes due 2021 | Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt | €						€ 750
Stated interest rate (as a percent)					0.50%	0.50%
Floating senior notes due 2021 | Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt		$ 750
Floating rate notes due 2023 | Term loan facilities
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross	$ 1,000			$ 1,000			1,000
Term loan credit agreement term	3 years			3 years
Floating rate notes due 2023, refinanced | Term loan facilities
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross	$ 1,000						$ 1,000
5% senior notes due 2021 | Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt	$ 1,200
Stated interest rate (as a percent)	5.00%						5.00%
May 2020 floating rate term loans | Term loan facilities
Debt and Credit Facilities [Line Items]
Principal amount of debt				$ 3,000
July 2019 term loan agreement | Term loan facilities
Debt and Credit Facilities [Line Items]
Maximum borrowing capacity of term loan credit agreement				6,000
Floating rate notes due 2025 | Term loan facilities
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross				$ 2,000
Term loan credit agreement term				5 years
Allergan notes exchanged | Senior notes
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross				$ 14,000
Allergan Euro notes exchanged | Senior notes
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross | €									€ 3,100
Allergan notes assumed | Senior notes
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross				1,500
Allergan Euro notes assumed | Senior notes
Debt and Credit Facilities [Line Items]
Long-term debt obligations, gross | €									€ 635
3.375% senior notes due 2020 | Senior notes
Debt and Credit Facilities [Line Items]
Stated interest rate (as a percent)	3.375%						3.375%
Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security			$ 650
2.5% senior notes due May 2020 | Senior notes
Debt and Credit Facilities [Line Items]
Repayments of long-term debt				$ 3,800
Stated interest rate (as a percent)				2.50%					2.50%

Financial Instruments and Fa_11

Financial Instruments and Fair Value Measures - Short-Term Borrowings (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Short-Term Borrowings [Line Items]
Short-term borrowings	$ 16,000,000	$ 34,000,000
Proceeds from Issuance of Commercial Paper	0
Commercial paper
Short-Term Borrowings [Line Items]
Short-term borrowings	$ 0	$ 0
Weighted-average interest rate on commercial paper (as a percent)			1.80%

Post-Employment Benefits (Detai

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Defined benefit plans
Defined benefit and other post-employment plans
Service cost	$ 110	$ 93	$ 331	$ 277
Interest cost	59	68	177	196
Expected return on plan assets	(166)	(148)	(498)	(426)
Amortization of prior service cost (credit)	1	1	2	2
Amortization of actuarial loss	72	56	217	169
Net periodic benefit cost	76	70	229	218
Other post-employment plans
Defined benefit and other post-employment plans
Service cost	12	10	36	31
Interest cost	5	8	14	25
Expected return on plan assets	0	0	0	0
Amortization of prior service cost (credit)	(10)	(1)	(29)	(3)
Amortization of actuarial loss	8	8	24	20
Net periodic benefit cost	$ 15	$ 25	$ 45	$ 73

Equity - Stock-Based Compensati

Equity - Stock-Based Compensation (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense		$ 135	$ 162	$ 563	$ 617
Tax benefit		27	32	101	109
After-tax compensation expense		108	130	462	508
AbbVie Amended and Restated 2013 Incentive Stock Program
Share-based Compensation Arrangement by Share-based Payment Award
Increase in number of shares available for issuance	44,000,000
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense		9	11	39	37
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense		47	54	181	200
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense		$ 79	$ 97	$ 343	$ 380

Equity - Stock Options (Details

Equity - Stock Options (Details) - Stock Options $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted (in shares) | shares	1.1
Weighted-average grant-date fair value of the stock options granted (in dollars per share) | $ / shares	$ 16.28
Unrecognized compensation cost | $	$ 12
Period for recognition of unrecognized compensation cost	2 years

Equity - RSUs and Performance S

Equity - RSUs and Performance Shares (Details) - RSUs and Performance Shares $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares) | shares	7.4
Fair market value of awards vested (in dollars per share) | $ / shares	$ 105.39
Unrecognized compensation cost | $	$ 712
Period for recognition of unrecognized compensation cost	2 years

Equity - Cash Dividends (Detail

Equity - Cash Dividends (Details) - $ / shares	Oct. 29, 2021	Sep. 10, 2021	Jun. 17, 2021	Feb. 18, 2021	Oct. 30, 2020	Sep. 11, 2020	Jun. 17, 2020	Feb. 20, 2020
Stockholders' Equity Note [Abstract]
Cash dividends declared per common share (in dollars per share)		$ 1.30	$ 1.30	$ 1.30	$ 1.30	$ 1.18	$ 1.18	$ 1.18
Dividends Payable
Cash dividends declared per common share (in dollars per share)		$ 1.30	$ 1.30	$ 1.30	$ 1.30	$ 1.18	$ 1.18	$ 1.18
Subsequent event
Stockholders' Equity Note [Abstract]
Cash dividends declared per common share (in dollars per share)	$ 1.41
Dividends Payable
Cash dividends declared per common share (in dollars per share)	$ 1.41

Equity - Stock Repurchase Progr

Equity - Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Equity, Class of Treasury Stock
Payment for shares repurchased	$ 6	$ 20	$ 803	$ 682
Remaining share repurchase authorization amount	$ 2,600		$ 2,600
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock
Shares repurchased (in shares)			5	6
Payment for shares repurchased			$ 550	$ 500

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance	$ 12,594	$ 14,732	$ 13,097	$ (8,172)
Other comprehensive income (loss)	(53)	176	(39)	337
Ending balance	13,577	15,289	13,577	15,289
Foreign currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			583	(928)
Other comprehensive income (loss) before reclassifications			(794)	726
Net losses (gains) reclassified from accumulated other comprehensive loss			0	0
Other comprehensive income (loss)			(794)	726
Ending balance	(211)	(202)	(211)	(202)
Net investment hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(790)	9
Other comprehensive income (loss) before reclassifications			457	(443)
Net losses (gains) reclassified from accumulated other comprehensive loss			(13)	(12)
Other comprehensive income (loss)			444	(455)
Ending balance	(346)	(446)	(346)	(446)
Pension and post-employment benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(3,067)	(2,965)
Other comprehensive income (loss) before reclassifications			27	(14)
Net losses (gains) reclassified from accumulated other comprehensive loss	56	50	169	148
Other comprehensive income (loss)			196	134
Ending balance	(2,871)	(2,831)	(2,871)	(2,831)
Cash flow hedging activities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			157	288
Other comprehensive income (loss) before reclassifications			60	(49)
Net losses (gains) reclassified from accumulated other comprehensive loss			55	(19)
Other comprehensive income (loss)			115	(68)
Ending balance	272	220	272	220
Accumulated other comprehensive income (loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax
Beginning balance			(3,117)	(3,596)
Other comprehensive income (loss) before reclassifications			(250)	220
Net losses (gains) reclassified from accumulated other comprehensive loss			211	117
Other comprehensive income (loss)			(39)	337
Ending balance	$ (3,156)	$ (3,259)	$ (3,156)	$ (3,259)

Equity - Amounts Reclassified O

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing		$ 585	$ 620	$ 1,813	$ 1,662
Tax expense (benefit)		508	187	1,214	321
Total reclassifications, net of tax		(3,179)	(2,308)	(7,498)	(4,580)
Losses (gains) on foreign currency forward exchange contracts		4,390	5,050	13,126	10,703
Pension and post-employment benefits
Significant amounts reclassified out of each component of AOCI
Amortization of actuarial losses and other	[1]	71	63	214	188
Tax benefit		(15)	(13)	(45)	(40)
Total reclassifications, net of tax		56	50	169	148
Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Total reclassifications, net of tax				55	(19)
Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Tax expense (benefit)		(4)	3	(9)	4
Total reclassifications, net of tax		24	(10)	55	(19)
Reclassification out of accumulated other comprehensive loss | Net investment hedges | Net investment hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	(7)	(3)	(16)	(16)
Tax expense (benefit)		1	1	3	4
Total reclassifications, net of tax		(6)	(2)	(13)	(12)
Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Losses (gains) on foreign currency forward exchange contracts	[3]	28	(15)	62	(15)
Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	(6)	(6)	(18)	(18)
Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gains on derivative amount excluded from effectiveness testing	[2]	$ 6	$ 8	$ 20	$ 10
[1]	(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).
[2]	(a) Amounts are included in interest expense, net (see Note 8)
[3]	(c) Amounts are included in cost of products sold (see Note 8).

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	14.00%	7.00%	14.00%	7.00%
U.S. statutory tax rate	21.00%	21.00%	21.00%	21.00%
Potential change in unrecognized tax benefits	$ 258		$ 258

Legal Proceedings and Conting_2

Legal Proceedings and Contingencies (Details) $ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2020company

Aug. 31, 2019company

Jun. 30, 2018USD ($)

Jun. 30, 2016investment_fund

Sep. 30, 2014company

May 31, 2019company

Sep. 30, 2021claimlawsuit

Sep. 30, 2021class_actionclaim

Sep. 30, 2021claimdirect_purchaser

Sep. 30, 2021end_payor_purchaserclaim

Sep. 30, 2021claimcompany

Sep. 30, 2021claiminvestment_fund

Jun. 30, 2020investment_fund

Niaspan

Legal Proceedings and Contingencies

Number of individual plaintiff lawsuits | lawsuit

4

Number of purported class actions | class_action

2

Number of healthcare benefit providers acting as plaintiff in lawsuit

1

1

AndroGel antitrust litigation, FTC v. AbbVie Inc.

Legal Proceedings and Contingencies

Number of generic companies with whom certain litigation related agreements were entered into

2

Number of generic companies named in claim whose court finding was reversed

1

AndroGel antitrust litigation, FTC v. AbbVie Inc. | Disgorgement remedy

Legal Proceedings and Contingencies

Damages awarded against company | $

$ 448

AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.

Legal Proceedings and Contingencies

Number of generic companies with whom certain litigation related agreements were entered into

3

Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation

Legal Proceedings and Contingencies

Number of individual putative class action lawsuits

12

Bystolic antitrust litigation

Legal Proceedings and Contingencies

Number of generic companies with whom certain litigation related agreements were entered into

6

Prescription drug abuse litigation

Legal Proceedings and Contingencies

Number of claims pending | claim

3,200

3,200

3,200

3,200

3,200

3,200

Prescription drug abuse litigation in state courts

Legal Proceedings and Contingencies

Number of claims pending | claim

300

300

300

300

300

300

Elliott Associates, L.P.

Legal Proceedings and Contingencies

Number of claims pending | investment_fund

1

Number of parties to lawsuit (in investment funds) | investment_fund

5

Number of plaintiff claims dismissed | investment_fund

3

Generic drug pricing securities litigation in U.S. District Court of New Jersey

Legal Proceedings and Contingencies

Number of individual plaintiff lawsuits | lawsuit

1

Number of purported class actions | class_action

3

Segment Information - Additiona

Segment Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Information - Disaggreg

Segment Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue
Total net revenues		$ 14,342	$ 12,902	$ 41,311	$ 31,946
All other
Disaggregation of Revenue
Net revenues	[1]	547	829	2,079	1,972
Immunology | Humira
Disaggregation of Revenue
Net revenues		5,425	5,140	15,360	14,680
Immunology | Humira | United States
Disaggregation of Revenue
Net revenues		4,613	4,189	12,777	11,819
Immunology | Humira | International
Disaggregation of Revenue
Net revenues		812	951	2,583	2,861
Immunology | Skyrizi
Disaggregation of Revenue
Net revenues		796	435	2,044	1,065
Immunology | Skyrizi | United States
Disaggregation of Revenue
Net revenues		679	379	1,725	934
Immunology | Skyrizi | International
Disaggregation of Revenue
Net revenues		117	56	319	131
Immunology | Rinvoq
Disaggregation of Revenue
Net revenues		453	215	1,134	450
Immunology | Rinvoq | United States
Disaggregation of Revenue
Net revenues		348	191	889	409
Immunology | Rinvoq | International
Disaggregation of Revenue
Net revenues		105	24	245	41
Hematologic Oncology | Imbruvica
Disaggregation of Revenue
Net revenues		1,374	1,370	4,023	3,890
Hematologic Oncology | Imbruvica | United States
Disaggregation of Revenue
Net revenues		1,109	1,119	3,207	3,140
Hematologic Oncology | Imbruvica | International
Disaggregation of Revenue
Collaboration revenues		265	251	816	750
Hematologic Oncology | Venclexta
Disaggregation of Revenue
Net revenues		492	352	1,332	972
Hematologic Oncology | Venclexta | United States
Disaggregation of Revenue
Net revenues		237	204	685	596
Hematologic Oncology | Venclexta | International
Disaggregation of Revenue
Net revenues		255	148	647	376
Aesthetics | Botox Cosmetic
Disaggregation of Revenue
Net revenues	[1]	545	393	1,606	619
Aesthetics | Botox Cosmetic | United States
Disaggregation of Revenue
Net revenues	[1]	356	237	1,027	384
Aesthetics | Botox Cosmetic | International
Disaggregation of Revenue
Net revenues	[1]	189	156	579	235
Aesthetics | Juvederm Collection
Disaggregation of Revenue
Net revenues	[1]	354	274	1,103	387
Aesthetics | Juvederm Collection | United States
Disaggregation of Revenue
Net revenues	[1]	159	115	478	171
Aesthetics | Juvederm Collection | International
Disaggregation of Revenue
Net revenues	[1]	195	159	625	216
Aesthetics | Other Aesthetics
Disaggregation of Revenue
Net revenues	[1]	352	300	1,117	442
Aesthetics | Other Aesthetics | United States
Disaggregation of Revenue
Net revenues	[1]	305	265	968	392
Aesthetics | Other Aesthetics | International
Disaggregation of Revenue
Net revenues	[1]	47	35	149	50
Neuroscience | Botox Therapeutic
Disaggregation of Revenue
Net revenues	[1]	645	523	1,780	820
Neuroscience | Botox Therapeutic | United States
Disaggregation of Revenue
Net revenues	[1]	534	429	1,451	683
Neuroscience | Botox Therapeutic | International
Disaggregation of Revenue
Net revenues	[1]	111	94	329	137
Neuroscience | Vraylar | United States
Disaggregation of Revenue
Net revenues	[1]	461	358	1,239	550
Neuroscience | Duodopa
Disaggregation of Revenue
Net revenues		127	123	383	365
Neuroscience | Duodopa | United States
Disaggregation of Revenue
Net revenues		23	25	73	75
Neuroscience | Duodopa | International
Disaggregation of Revenue
Net revenues		104	98	310	290
Neuroscience | Ubrelvy | United States
Disaggregation of Revenue
Net revenues	[1]	162	38	369	60
Neuroscience | Other Neuroscience
Disaggregation of Revenue
Net revenues	[1]	171	207	502	312
Neuroscience | Other Neuroscience | United States
Disaggregation of Revenue
Net revenues	[1]	166	203	489	306
Neuroscience | Other Neuroscience | International
Disaggregation of Revenue
Net revenues	[1]	5	4	13	6
Eye Care | Lumigan/Ganfort
Disaggregation of Revenue
Net revenues	[1]	138	149	430	225
Eye Care | Lumigan/Ganfort | United States
Disaggregation of Revenue
Net revenues	[1]	63	62	201	97
Eye Care | Lumigan/Ganfort | International
Disaggregation of Revenue
Net revenues	[1]	75	87	229	128
Eye Care | Alphagan/Combigan
Disaggregation of Revenue
Net revenues	[1]	128	123	388	192
Eye Care | Alphagan/Combigan | United States
Disaggregation of Revenue
Net revenues	[1]	89	84	271	131
Eye Care | Alphagan/Combigan | International
Disaggregation of Revenue
Net revenues	[1]	39	39	117	61
Eye Care | Restasis
Disaggregation of Revenue
Net revenues	[1]	319	299	926	443
Eye Care | Restasis | United States
Disaggregation of Revenue
Net revenues	[1]	305	284	884	422
Eye Care | Restasis | International
Disaggregation of Revenue
Net revenues	[1]	14	15	42	21
Eye Care | Other Eye Care
Disaggregation of Revenue
Net revenues	[1]	286	269	863	397
Eye Care | Other Eye Care | United States
Disaggregation of Revenue
Net revenues	[1]	128	119	375	173
Eye Care | Other Eye Care | International
Disaggregation of Revenue
Net revenues	[1]	158	150	488	224
Women's Health | Lo Loestrin
Disaggregation of Revenue
Net revenues	[1]	107	134	309	214
Women's Health | Lo Loestrin | United States
Disaggregation of Revenue
Net revenues	[1]	105	129	300	207
Women's Health | Lo Loestrin | International
Disaggregation of Revenue
Net revenues	[1]	2	5	9	7
Women's Health | Orilissa/Oriahnn
Disaggregation of Revenue
Net revenues		38	25	106	87
Women's Health | Orilissa/Oriahnn | United States
Disaggregation of Revenue
Net revenues		37	24	102	84
Women's Health | Orilissa/Oriahnn | International
Disaggregation of Revenue
Net revenues		1	1	4	3
Women's Health | Other Women's Health
Disaggregation of Revenue
Net revenues	[1]	57	80	158	116
Women's Health | Other Women's Health | United States
Disaggregation of Revenue
Net revenues	[1]	57	74	153	108
Women's Health | Other Women's Health | International
Disaggregation of Revenue
Net revenues	[1]	0	6	5	8
Other Key Products | Mavyret
Disaggregation of Revenue
Net revenues		426	414	1,283	1,349
Other Key Products | Mavyret | United States
Disaggregation of Revenue
Net revenues		183	185	557	565
Other Key Products | Mavyret | International
Disaggregation of Revenue
Net revenues		243	229	726	784
Other Key Products | Creon | United States
Disaggregation of Revenue
Net revenues		310	282	864	810
Other Key Products | Lupron
Disaggregation of Revenue
Net revenues		180	133	591	571
Other Key Products | Lupron | United States
Disaggregation of Revenue
Net revenues		134	99	456	461
Other Key Products | Lupron | International
Disaggregation of Revenue
Net revenues		46	34	135	110
Other Key Products | Linzess/Constella
Disaggregation of Revenue
Net revenues	[1]	261	248	751	381
Other Key Products | Linzess/Constella | United States
Disaggregation of Revenue
Net revenues	[1]	253	240	728	370
Other Key Products | Linzess/Constella | International
Disaggregation of Revenue
Net revenues	[1]	8	8	23	11
Other Key Products | Synthroid | United States
Disaggregation of Revenue
Net revenues		$ 188	$ 189	$ 571	$ 577
[1]	(a) Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.